US 12,247,075 B2
BTN3A binding proteins and uses thereof
Alemseged Truneh, Sudbury, MA (US); Christine Pasero, Marseilles (FR); René Hoet, Marseilles (FR); Magali Colazet, Marseilles (FR); and Daniel Olive, Marseilles (FR)
Assigned to IMCHECK THERAPEUTICS SAS, Marseilles (FR); INSTITUT JEAN PAOLI & IRENE CALMETTES, Marseilles (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, Paris (FR); INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), Paris (FR); and UNIVERSITE D'AIX-MARSEILLE, Marseilles (FR)
Appl. No. 17/418,017
Filed by IMCHECK THERAPEUTICS SAS, Marseilles (FR); INSTITUT JEAN PAOLI & IRENE CALMETTES, Marseilles (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, Paris (FR); INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Paris (FR); and UNIVERSITÉ D'AIX-MARSEILLE, Marseilles (FR)
PCT Filed Dec. 26, 2019, PCT No. PCT/EP2019/087040
§ 371(c)(1), (2) Date Jun. 24, 2021,
PCT Pub. No. WO2020/136218, PCT Pub. Date Jul. 2, 2020.
Claims priority of application No. 18306845 (EP), filed on Dec. 26, 2018.
Prior Publication US 2022/0073619 A1, Mar. 10, 2022
Int. Cl. C07K 16/28 (2006.01); C12N 15/63 (2006.01)
CPC C07K 16/2827 (2013.01) [C12N 15/63 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/75 (2013.01); C07K 2317/92 (2013.01)] 9 Claims
 
1. An isolated anti-BTN3A antibody, or a fragment thereof, having
(i) a heavy chain variable region (VH) comprising a H-CDR1 of SEQ ID NO: 1, H-CDR-2 of SEQ ID NO:2, and H-CDR3 of SEQ ID NO:3; and,
a light chain variable region (VL) comprising a L-CDR1 of SEQ ID NO:4, a L-CDR2 of SEQ ID NO: 17, and a L-CDR3 of SEQ ID NO: 6.